Keywords
How to Cite
Abstract
Annotatsiya: Mazkur maqolada differensiyalashgan qalqonsimon bez saratonida qo‘llaniladigan target (maqsadli) terapiyaning o‘rni va samaradorligi yoritilgan. Radioyodga rezistent yoki metastatik shakllarda molekulyar nishonlarga ta’sir etuvchi preparatlar qo‘llanilishi kasallik rivojlanishini sekinlashtirishda muhim ahamiyat kasb etadi. Target terapiya o‘sma hujayralarining o‘sish va proliferatsiya mexanizmlariga ta’sir ko‘rsatib, sog‘lom to‘qimalarga nisbatan kamroq zarar yetkazadi. Maqolada ushbu davolash usulining ko‘rsatmalari, nojo‘ya ta’sirlari va klinik natijalari tahlil qilingan.
References
1. Haugen B.R., Alexander E.K., Bible K.C. et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid.
2. Schlumberger M., Tahara M., Wirth L.J. et al. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine.
3. Brose M.S., Nutting C.M., Jarzab B. et al. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. The Lancet.
4. Sherman S.I. (2018). Targeted therapy of thyroid cancer. Biochemical and Biophysical Research Communications.
5. NCCN Clinical Practice Guidelines in Oncology. (So‘nggi nashri). Thyroid Carcinoma.